These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6827912)

  • 1. Inhibition of sparteine oxidation in human liver by tricyclic antidepressants and other drugs.
    Otton SV; Inaba T; Kalow W
    Life Sci; 1983 Feb; 32(7):795-800. PubMed ID: 6827912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
    Brøsen K; Gram LF; Kragh-Sørensen P
    Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.
    Otton SV; Inaba T; Kalow W
    Life Sci; 1984 Jan; 34(1):73-80. PubMed ID: 6141510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.
    Otton SV; Inaba T; Mahon WA; Kalow W
    Can J Physiol Pharmacol; 1982 Jan; 60(1):102-5. PubMed ID: 7066751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sparteine oxidation by the human liver: absence of inhibition by mephenytoin.
    Jurima M; Inaba T; Kalow W
    Clin Pharmacol Ther; 1984 Mar; 35(3):426-8. PubMed ID: 6697650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition and metabolite complexation of rat hepatic microsomal cytochrome P450 by tricyclic antidepressants.
    Murray M; Field SL
    Biochem Pharmacol; 1992 May; 43(10):2065-71. PubMed ID: 1599495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of cytochrome P450 2D6-catalyzed sparteine metabolism in humans.
    Ebner T; Meese CO; Eichelbaum M
    Mol Pharmacol; 1995 Dec; 48(6):1078-86. PubMed ID: 8848008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymorphic drug oxidation in humans.
    Eichelbaum M
    Fed Proc; 1984 May; 43(8):2298-302. PubMed ID: 6714436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct and indirect interactions between antidepressant drugs and CYP2C6 in the rat liver during long-term treatment.
    Daniel WA; Haduch A; Syrek M; Boksa J
    Eur Neuropsychopharmacol; 2006 Dec; 16(8):580-7. PubMed ID: 16503401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
    Fonne-Pfister R; Meyer UA
    Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype.
    Brøsen K; Otton SV; Gram LF
    Clin Pharmacol Ther; 1986 Nov; 40(5):543-9. PubMed ID: 3769385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
    Brøsen K; Gram LF
    Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficient metabolism of debrisoquine and sparteine.
    Inaba T; Otton SV; Kalow W
    Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin.
    Shin JG; Park JY; Kim MJ; Shon JH; Yoon YR; Cha IJ; Lee SS; Oh SW; Kim SW; Flockhart DA
    Drug Metab Dispos; 2002 Oct; 30(10):1102-7. PubMed ID: 12228186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry.
    Tyndale RF; Gonzalez FJ; Hardwick JP; Kalow W; Inaba T
    Pharmacol Toxicol; 1990 Jul; 67(1):14-8. PubMed ID: 2395811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defective oxidation of drugs: pharmacokinetic and therapeutic implications.
    Eichelbaum M
    Clin Pharmacokinet; 1982; 7(1):1-22. PubMed ID: 7042170
    [No Abstract]   [Full Text] [Related]  

  • 17. Role of P450IID6, the target of the sparteine-debrisoquin oxidation polymorphism, in the metabolism of imipramine.
    Brøsen K; Zeugin T; Meyer UA
    Clin Pharmacol Ther; 1991 Jun; 49(6):609-17. PubMed ID: 2060250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
    Brosen K
    Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tricyclic antidepressants amitriptyline, nortriptyline and imipramine are weak antagonists of human and rat alpha1B-adrenoceptors.
    Nojimoto FD; Mueller A; Hebeler-Barbosa F; Akinaga J; Lima V; Kiguti LR; Pupo AS
    Neuropharmacology; 2010; 59(1-2):49-57. PubMed ID: 20363235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
    Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
    J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.